Strong Phase III Xtandi data could give Pfizer and Astellas a boost

6 February 2018

Japan’s Astellas Pharma (TYO: 4503) and development partner Pfizer (NYSE: PFE) have made public the data powering US and EU regulatory submissions for Xtandi (enzalutamide) in prostate cancer.

Data from the Phase III PROSPER trial show that adding treatment with the androgen receptor inhibitor to regular hormone therapy reduced the risk of metstases or death by 71%.

Analysts believe the strong efficacy data could impact significantly on prescribing practices for Xtandi, which was the chief attraction in the portfolio of Medivation, the San Franciscan biotech acquired by Pfizer for $14 billion in 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK